ConductScience.org, home
A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)
API referenceFor AI assistants

Trial · NCT01904721

Results by group81

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 20 of 81

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Change From Baseline in Target Area Hair Count (TAHC)Stage 2: Bimatoprost Solution 2 Twice DailyBaseline131.3Standard Deviation 55.53terminal hairs/cm2
Change From Baseline in Target Area Hair Count (TAHC)Stage 2: Bimatoprost Solution 1 Twice DailyBaseline140.4Standard Deviation 59.76terminal hairs/cm2
Change From Baseline in Target Area Hair Count (TAHC)Stage 2: Bimatoprost Vehicle Twice DailyBaseline129.0Standard Deviation 57.42terminal hairs/cm2
Change From Baseline in Target Area Hair Count (TAHC)Stage 2: Bimatoprost Solution 2 Twice DailyChange from Baseline at Month 69.3Standard Deviation 23.09terminal hairs/cm2
Change From Baseline in Target Area Hair Count (TAHC)Stage 2: Bimatoprost Solution 1 Twice DailyChange from Baseline at Month 612.7Standard Deviation 26.39terminal hairs/cm2
Change From Baseline in Target Area Hair Count (TAHC)Stage 2: Bimatoprost Vehicle Twice DailyChange from Baseline at Month 65.8Standard Deviation 20.95terminal hairs/cm2
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 2 Twice DailyGreatly increased4.8Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 1 Twice DailyGreatly increased6.5Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Vehicle Twice DailyGreatly increased0.0Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 2 Twice DailyModerately increased25.4Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 1 Twice DailyModerately increased14.5Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Vehicle Twice DailyModerately increased6.7Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 2 Twice DailySlightly increased33.3Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 1 Twice DailySlightly increased33.9Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Vehicle Twice DailySlightly increased20.0Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 2 Twice DailyRemained the same23.8Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 1 Twice DailyRemained the same30.6Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Vehicle Twice DailyRemained the same35.0Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 2 Twice DailySlightly decreased12.7Percentage of Participants
Percentage of Participants in Each Response Category of the Subject Self Assessment in Alopecia (SSA) ScoreStage 2: Bimatoprost Solution 1 Twice DailySlightly decreased12.9Percentage of Participants

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01904721/results

API referenceFor AI assistants